Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...

Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...

Plus: Blue Origin and SpaceX launch big rockets, how magnets could guide lasers to make better computers, how to best work ...

OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan.

Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in ...

OpenAI CEO Sam Altman backs Retro Biosciences, a San Francisco-based biotech start-up that wants to extend human lifespan by ...

OpenAI has created a ChatGPT model called GPT-4b micro for Retro Biosciences, a longevity research company - here's what it ...

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

ChatGPT publisher, OpenAI, has teamed up with a longevity start-up to develop an artificial intelligence model dedicated to ...

Disease-reversal startup Retro Biosciences is aiming for a $1 billion funding round, a spokesperson for the company confirmed ...